FORECAST: IDIOPATHIC PULMONARY FIBROSIS (Published on 17 November 2017)
Overview
Executive Summary
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Esbriet
Product Profile: Ofev
TREATMENT: IDIOPATHIC PULMONARY FIBROSIS (Published on 06 November 2017)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
EPIDEMIOLOGY: IDIOPATHIC PULMONARY FIBROSIS (Published on 07 August 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources
MARKETED DRUGS: IDIOPATHIC PULMONARY FIBROSIS (Published on 17 November 2017)
Overview
Executive Summary
Product Overview
Product Profile: Esbriet
Product Profile: Ofev
PIPELINE: IDIOPATHIC PULMONARY FIBROSIS (Published on 17 November 2017)
Overview
Executive Summary
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Glpg1690
Product Profile (Late Stage): Pbi-4050
Product Profile (Late Stage): Prm-151
Product Profile (Late Stage): Pamrevlumab
LIST OF FIGURES
Figure 1: Idiopathic pulmonary fibrosis – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for idiopathic pulmonary fibrosis
Figure 3: Idiopathic pulmonary fibrosis drug sales across the US, Japan, and five major EU markets, by country, 2016–25
Figure 4: Idiopathic pulmonary fibrosis drug sales in the US, 2016–25
Figure 5: Total sales categorized by severity across the US, Japan, and five major EU markets, 2016–25
Figure 6: Patient-based forecast methodology for idiopathic pulmonary fibrosis
Figure 7: Price sources and calculations, by country
Figure 8: Esbriet for idiopathic pulmonary fibrosis – SWOT analysis
Figure 9: The authors drug assessment summary of Esbriet for idiopathic pulmonary fibrosis
Figure 10: The authors drug assessment summary of Esbriet for idiopathic pulmonary fibrosis
Figure 11: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 12: Ofev for idiopathic pulmonary fibrosis – SWOT analysis
Figure 13: The authors drug assessment summary of Ofev for idiopathic pulmonary fibrosis
Figure 14: The authors drug assessment summary of Ofev for idiopathic pulmonary fibrosis
Figure 15: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 16: Distribution of diagnosed idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by severity and country (%)
Figure 17: Estimated percentage of idiopathic pulmonary fibrosis patients in each severity who remain undiagnosed across the US, Japan, and five major EU markets
Figure 18: Estimated percentage of IPF patients who experience acute exacerbation in the US, Japan, and five major EU markets, by severity and country
Figure 19: Overview of the ATS/ERS/JRS/ALAT evidence-based guidelines for the treatment of idiopathic pulmonary fibrosis
Figure 20: Percentage of IPF patients who fall into each treatment category in the US, Japan, and five major EU markets, by severity and country
Figure 21: Top five pharmacological treatment regimens used in mild IPF patients across the US, Japan, and five major EU markets, by country
Figure 22: Top five pharmacological treatment regimens used in moderate IPF patients across the US, Japan, and five major EU markets, by country
Figure 23: Top five pharmacological treatment regimens used in severe IPF patients across the US, Japan, and five major EU markets, by country
Figure 24: Use of Esbriet and Ofev, whether alone or in a combination, across the US, Japan, and five major EU markets, by severity and country
Figure 25: Percentage use of Esbriet and Ofev as monotherapy and in each combination across the US, Japan, and five major EU markets, by severity
Figure 26: Patients who receive supplemental anti-gastroesophageal reflux medications across the US, Japan, and five major EU markets, by severity and country (%)
Figure 27: Non-pharmacological treatments used in mild idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
Figure 28: Non-pharmacological treatments used in moderate idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
Figure 29: Non-pharmacological treatments used in severe idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
Figure 30: Trends in diagnosed incident cases of IPF in the US, Japan, and five major EU markets, by country, 2017–37
Figure 31: Trends in diagnosed prevalent cases of IPF in the US, Japan, and five major EU markets, by country, 2017–37
Figure 32: Esbriet for idiopathic pulmonary fibrosis – SWOT analysis
Figure 33: The authors drug assessment summary of Esbriet for idiopathic pulmonary fibrosis
Figure 34: The authors drug assessment summary of Esbriet for idiopathic pulmonary fibrosis
Figure 35: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 36: Ofev for idiopathic pulmonary fibrosis – SWOT analysis
Figure 37: The authors drug assessment summary of Ofev for idiopathic pulmonary fibrosis
Figure 38: The authors drug assessment summary of Ofev for idiopathic pulmonary fibrosis
Figure 39: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 40: GLPG1690 for idiopathic pulmonary fibrosis – SWOT analysis
Figure 41: The authors drug assessment summary of GLPG1690 for idiopathic pulmonary fibrosis
Figure 42: The authors drug assessment summary of GLPG1690 for idiopathic pulmonary fibrosis
Figure 43: PBI-4050 for idiopathic pulmonary fibrosis – SWOT analysis
Figure 44: The authors drug assessment summary of PBI-4050 for idiopathic pulmonary fibrosis
Figure 45: The authors drug assessment summary of PBI-4050 for idiopathic pulmonary fibrosis
Figure 46: PRM-151 for idiopathic pulmonary fibrosis – SWOT analysis
Figure 47: The authors drug assessment summary of PRM-151 for idiopathic pulmonary fibrosis
Figure 48: The authors drug assessment summary of PRM-151 for idiopathic pulmonary fibrosis
Figure 49: Pamrevlumab for idiopathic pulmonary fibrosis – SWOT analysis
Figure 50: The authors drug assessment summary of pamrevlumab for idiopathic pulmonary fibrosis
Figure 51: The authors drug assessment summary of pamrevlumab for idiopathic pulmonary fibrosis
LIST OF TABLES
Table 1: Summary of drug classes and molecules included in The authors idiopathic pulmonary fibrosis patientbased forecast
Table 2: Exchange rates used for calculating prices
Table 3: Pulmonologists surveyed for the idiopathic pulmonary fibrosis primary research study, 2015
Table 4: Esbriet drug profile
Table 5: Esbriet Phase III data in idiopathic pulmonary fibrosis
Table 6: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 7: Ofev drug profile
Table 8: Ofev pivotal trial data in idiopathic pulmonary fibrosis
Table 9: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 10: Pulmonologists surveyed for the idiopathic pulmonary fibrosis primary research study, 2015
Table 11: Subtypes of idiopathic interstitial pneumonias
Table 12: The authors definition of idiopathic pulmonary fibrosis severity
Table 13: Estimated percentage of idiopathic pulmonary fibrosis patients in each severity who remain undiagnosed across the US, Japan, and five major EU markets
Table 14: Approved treatments available for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets
Table 15: Off-label therapies used in the treatment of idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets
Table 16: Non-pharmacological therapies used in the treatment of idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets
Table 17: Pharmacological treatment regimens used in mild idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
Table 18: Pharmacological treatment regimens used in moderate idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
Table 19: Pharmacological treatment regimens used in severe idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
Table 20: Sources used for the epidemiological analysis of IPF in the US, Japan, and five major EU markets, by country
Table 21: Diagnosed incident cases of IPF in the US, Japan, and five major EU markets, by country, 2017–37
Table 22: Diagnosed prevalent cases of IPF in the US, Japan, and five major EU markets, by country, 2017–37
Table 23: Profiled key marketed drugs for idiopathic pulmonary fibrosis
Table 24: Esbriet drug profile
Table 25: Esbriet Phase III data in idiopathic pulmonary fibrosis
Table 26: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 27: Ofev drug profile
Table 28: Ofev pivotal trial data in idiopathic pulmonary fibrosis
Table 29: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 30: Phase II pipeline products in development for idiopathic pulmonary fibrosis
Table 31: GLPG1690 drug profile
Table 32: GLPG1690 Phase II data in idiopathic pulmonary fibrosis
Table 33: PBI-4050 drug profile
Table 34: PBI-4050 Phase II data in idiopathic pulmonary fibrosis
Table 35: PRM-151 drug profile
Table 36: PRM-151 Phase II trial in idiopathic pulmonary fibrosis
Table 37: PRM-151 Phase I data in idiopathic pulmonary fibrosis
Table 38: Pamrevlumab drug profile
Table 39: Pamrevlumab Phase II data in idiopathic pulmonary fibrosis
